Diversity at Risk in Disrupted Clinical Trials

Clinical trials face major disruptions that threaten diversity in medical research, a critical goal pushed by bureaucrats but now crumbling under real-world pressures. EurekAlert reports JMIR news highlighting how these setbacks undermine efforts to include varied populations, potentially delaying treatments for everyday Americans. Big government mandates for diversity sound good on paper, but when trials halt, it's patients who suffer from slower innovation and less reliable drugs. Read more about this...